• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 25406-64-8 Price $100 / 20mg
    Catalog No.CFN98161Purity>=98%
    Molecular Weight406.38Type of CompoundIridoids
    FormulaC17H26O11Physical DescriptionWhite powder
    Download Manual    COA    MSDS    SDFSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Utah State University (USA)
  • Uniwersytet Jagielloński w Krak... (Poland)
  • Funda??o Universitária de Desen... (Brazil)
  • Seoul National University (Korea)
  • Celltrion Chemical Research Inst... (Korea)
  • University of Pretoria (South Africa)
  • Yale University (USA)
  • Medizinische Universit?t Wien (Austria)
  • Amity University (India)
  • Warszawski Uniwersytet Medyczny (Poland)
  • Universite de Lille1 (France)
  • More...
  • Package
    Featured Products
    3-O-Caffeoylquinic acid methyl ester

    Catalog No: CFN92573
    CAS No: 123483-19-2
    Price: $198/10mg

    Catalog No: CFN92154
    CAS No: 69618-96-8
    Price: $463/5mg

    Catalog No: CFN99907
    CAS No: 517-88-4
    Price: $80/20mg

    Catalog No: CFN97049
    CAS No: 61303-13-7
    Price: $178/20mg
    Alisol C

    Catalog No: CFN92545
    CAS No: 30489-27-1
    Price: $388/5mg
    Morroniside Description
    Source: The herbs of Lonicera morrowii
    Biological Activity or Inhibitors: 1. Morroniside would act as a regulator of hepatic inflammatory reactions and lipid metabolism in db/db mice.
    2. Morroniside exhibits protective effects against diabetic renal damage and human umbilical vein endothelial cells , by inhibiting hyperglycemia and oxidative stress.
    3. Morroniside can notably protect the brain from damage induced by focal cerebral ischemia which might be related to morroniside antioxidant and anti-apoptotic properties in the brain.
    Solvent: Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.4608 mL 12.3038 mL 24.6075 mL 49.215 mL 61.5188 mL
    5 mM 0.4922 mL 2.4608 mL 4.9215 mL 9.843 mL 12.3038 mL
    10 mM 0.2461 mL 1.2304 mL 2.4608 mL 4.9215 mL 6.1519 mL
    50 mM 0.0492 mL 0.2461 mL 0.4922 mL 0.9843 mL 1.2304 mL
    100 mM 0.0246 mL 0.123 mL 0.2461 mL 0.4922 mL 0.6152 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Morroniside References Information
    Citation [1]

    J Pharmacol Sci. 2015 Apr;127(4):414-8.

    Induction of CYP3A by morroniside in rats.[Pubmed: 25953268]
    Morroniside is one of the most important iridoid glycosides in the herbal drug Cornus officinalis Sieb. et Zucc. The current study was designed to investigate the ex vivo and in vivo effects of Morroniside on CYP3A activity in rats after treatment with Morroniside for 7 days (at 10, 30, 90 mg/kg, i.g.). Morroniside was found to induce CYP3A. According to the ex vivo experiment, the activity of CYP3A was measured by the quantification of 1-hydroxymidazolam, which was the metabolite from CYP3A probe substrate, midazolam. The concentration of 1-hydroxymidazolam was determined by using a validated liquid chromatography coupled with tandem mass spectrometry detection (LC-MS/MS) method. The levels of messenger RNA (mRNA) and protein of CYP3A were determined by reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting analysis, respectively. The pharmacokinetics of midazolam in rats after treatment with Morroniside for 7 days (at 10, 30, 90 mg/kg, i.g.) were investigated in vivo. After treatment with Morroniside, the activity, mRNA and protein expression of CYP3A were significantly induced and the absorbance and bioavailability of midazolam in rats were reduced. The results indicated that Morroniside could induce the activity of CYP3A.
    Citation [2]

    Eur J Pharmacol. 2014 Sep 5;738:214-21.

    Promoting neurogenesis via Wnt/β-catenin signaling pathway accounts for the neurorestorative effects of morroniside against cerebral ischemia injury.[Pubmed: 24876057]
    Ischemic stroke is a leading cause of mortality and permanent disability in adults worldwide. Neurogenesis triggered by ischemia in the adult mammalian brain may provide insights into stroke treatment. Morroniside is an active component of sarcocarp of C. officinalis that have shown neuroprotective effects. The aim of the present study is to test whether Morroniside promotes neurogenesis via Wnt/β-catenin signaling pathway for brain recovery in a rat model of focal cerebral ischemia. Morroniside was administered intragastrically once daily at the concentrations of 30, 90 and 270 mg/kg for 7 days post-ischemia. Neurological functions were detected by Ludmila Belayev score tests. Endogenous neural stem cells responses were investigated with immunofluorescence staining of Ki-67 and Nestin to identify the neurogenesis in the subventricular zone (SVZ). The expression of proteins involved in and related to Wnt/β-catenin signaling pathway was detected by western blotting analysis. Morroniside significantly promoted neurogenesis for brain recovery 7 days post-ischemia. Increased expression of Wnt 3a, β-catenin and T-cell transcription factor-4 (Tcf-4), along with activation of downstream transcription factors Pax6 and neurogenin2 (Ngn2), indicated that the neurorestorative effects of Morroniside may be associated with Wnt/β-catenin signaling pathway. These data provide support for understanding the mechanisms of Morroniside in neurorestorative effects and suggest a potential new strategy for ischemic stroke treatment.
    Citation [3]

    J Cell Mol Med. 2015 Mar 5.

    Protein kinase B and extracellular signal-regulated kinase contribute to the chondroprotective effect of morroniside on osteoarthritis chondrocytes.[Pubmed: 25754021]
    Despite extensive studies on the multifaceted roles of Morroniside, the main active constituent of iridoid glycoside from Corni Fructus, the effect of Morroniside on osteoarthritis (OA) chondrocytes remains poorly understood. Here, we investigated the influence of Morroniside on cultured human OA chondrocytes and a rat experimental model of OA. The results showed that Morroniside enhanced the cell viability and the levels of proliferating cell nuclear antigen expression (PCNA), type II collagen and aggrecan in human OA chondrocytes, indicating that Morroniside promoted chondrocyte survival and matrix synthesis. Furthermore, different doses of Morroniside activated protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) in human OA chondrocytes, and in turn, triggered AKT/S6 and ERK/P70S6K/S6 pathway, respectively. The PI3K/AKT inhibitor LY294002 or the MEK/ERK inhibitor U0126 attenuated the effect of Morroniside on human OA chondrocytes, indicating that the activation of AKT and ERK contributed to the regulation of Morroniside in human OA chondrocytes. In addition, the intra-articular injection of Morroniside elevated the level of proteoglycans in cartilage matrix and the thickness of articular cartilage in a rat experimental model of OA, with the increase of AKT and ERK activation. As a consequence, Morroniside has chondroprotective effect on OA chondrocytes, and may have the therapeutic potential for OA treatment.
    Citation [4]

    PLoS One. 2014 Jun 30;9(6):e101194.

    Morroniside improves microvascular functional integrity of the neurovascular unit after cerebral ischemia.[Pubmed: 24979385]
    We demonstrated that at 3 days post-ischemia, Morroniside preserved neurovascular unit function by ameliorating BBB injury. By 7 days post-ischemia, Morroniside amplified angiogenesis, in part by enhancing endothelial progenitor cell proliferation and expression of angiogenic factors. Morever, the increase in the amount of vWF+ vessels induced by ischemia could be extended to 28 days after administration of Morroniside, indicating the crucial role of Morroniside in angiogenesis during the chronic phase. Taken together, our findings suggested that Morroniside might offer a novel therapeutic approach for promoting microvascular integrity recovery and provide a thoroughly new direction for stroke therapy.
    Citation [5]

    Mol Med Rep. 2013 May;7(5):1565-70.

    Morroniside promotes bone marrow mesenchymal stem cell proliferation in rats.[Pubmed: 23546017]
    The aim of this study was to explore the mechanism underlying the promotive effect of Morroniside on rat mesenchymal stem cell (RMSC) proliferation and to provide an experimental basis for the development of potential new drugs. RMSCs were obtained from the bone marrow of Sprague-Dawley rats aged 3-4 months. The proliferation of primary and subcultured RMSCs in the high‑, medium‑ and low‑concentration Morroniside intervention and blank control groups was observed using light microscopy. Cell proliferation and survival conditions were detected using methyl thiazolyl tetrazolium (MTT) colorimetric tests. Light microscopy and the MTT assay revealed that RMSC adherence time in the Morroniside groups was shorter compared with that of the control group. Twelve hours after the media of primary RMSCs were changed, the number of adherent cells in the Morroniside groups increased and an elongated cell morphology was observed. The cells at the fourth passage in the Morroniside groups fused completely 12‑16 h after inoculation and then rapidly entered into the logarithmic phase. The primary RMSCs of the Morroniside intervention groups grew into typical bone marrow mesenchymal stem cell (BMSC) colonies after 4 days of Morroniside treatment and their fusion rate had reached 80% after 9‑11 days. By contrast, the cell fusion rate of the control group only reached 75-80% after 14 days of Morroniside treatment. Morroniside exhibited a similar promotive effect on proliferation in primary and subcultured RMSCs. Morroniside may promote RMSC proliferation through secreted factors, cell-to-cell interactions and/or the interactions between cellular adhesion molecules and extracellular matrices (ECMs). However, the specific mechanism underlying this effect remains to be fully elucidated.